{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:57:14Z","timestamp":1776153434056,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10626-2","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:14:11Z","timestamp":1776150851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["International Utah cardiac recovery symposium (U-CARS) 2025:translational and basic science proceedings"],"prefix":"10.1007","volume":"31","author":[{"given":"Joseph R.","family":"Visker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Tseliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Drosatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Wever-Pinzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros G.","family":"Drakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"11","key":"10626_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s44161-022-00157-y","volume":"1","author":"A Papa","year":"2022","unstructured":"Papa A, Zakharov SI, Katchman AN et al (2022) Rad regulation of CaV1.2 channels controls cardiac fight-or-flight response. Nat Cardiovasc Res 1(11):1022\u20131038","journal-title":"Nat Cardiovasc Res"},{"key":"10626_CR2","doi-asserted-by":"crossref","unstructured":"2. Katchman AN, Zakharov SI, Bohnen MS, et al. Augmented cardiac inotropy by phosphodiesterase inhibition requires phosphorylation of Rad and increased calcium current. Circulation. 2024 May 14;149(20):1617\u20131620.","DOI":"10.1161\/CIRCULATIONAHA.123.067298"},{"issue":"12","key":"10626_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41588-024-01975-5","volume":"56","author":"SJ Jurgens","year":"2024","unstructured":"Jurgens SJ, R\u00e4m\u00f6 JT, Kramarenko DR et al (2024) Genome-wide association study reveals mechanisms underlying dilated cardiomyopathy and myocardial resilience. Nat Genet 56(12):2636\u20132645","journal-title":"Nat Genet"},{"issue":"20","key":"10626_CR4","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1113\/JP280801","volume":"599","author":"RD Harvey","year":"2021","unstructured":"Harvey RD, Clancy CE (2021) Mechanisms of cAMP compartmentation in cardiac myocytes: experimental and computational approaches to understanding. J Physiol 599(20):4527\u20134544","journal-title":"J Physiol"},{"issue":"7","key":"10626_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1113\/JP279385","volume":"598","author":"DM Bers","year":"2020","unstructured":"Bers DM, Kim Y-I (2020) Mechanics and energetics in cardiac arrhythmias and heart failure. J Physiol 598(7):1275\u20131277","journal-title":"J Physiol"},{"key":"10626_CR6","doi-asserted-by":"crossref","unstructured":"6. Muller GK, Song J, Jani V, et al. PDE1 inhibition modulates CaV1.2 channel to stimulate cardiomyocyte contraction. Circ Res. 2021 Oct 15;129(9):872\u2013886.","DOI":"10.1161\/CIRCRESAHA.121.319828"},{"issue":"1","key":"10626_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41589-023-01381-8","volume":"20","author":"TY Lin","year":"2024","unstructured":"Lin TY, Mai QN, Zhang H et al (2024) Cardiac contraction and relaxation are regulated by distinct subcellular cAMP pools. Nat Chem Biol 20(1):62\u201373","journal-title":"Nat Chem Biol"},{"key":"10626_CR8","doi-asserted-by":"crossref","unstructured":"8. Wo\u0142owiec \u0141, Grze\u015bk G, Osiak J, et al. Beta-blockers in cardiac arrhythmias\u2013Clinical pharmacologist\u2019s point of view. Front Pharmacol. 2023 Jan 9;13:1043714.","DOI":"10.3389\/fphar.2022.1043714"},{"key":"10626_CR9","doi-asserted-by":"crossref","unstructured":"9. Shannon TR, Bare DJ, van Dijk S, et al. Subcellular propagation of cardiomyocyte \u03b2-adrenergic activation of calcium uptake involves internal \u03b2-receptors and AKAP7. Function (Oxf). 2022 May 5;3(3):zqac020.","DOI":"10.1093\/function\/zqac020"},{"key":"10626_CR10","doi-asserted-by":"crossref","unstructured":"10. Grogan A, Lucero EY, Jiang H, et al. Pathophysiology and pharmacology of G protein-coupled receptors in the heart. Cardiovasc Res. 2023 May 22;119(5):1117\u20131129.","DOI":"10.1093\/cvr\/cvac171"},{"key":"10626_CR11","unstructured":"11. Kahsai AW, Pakharukova N, Kwon HY, et al. Small molecule modulators of \u03b2-arrestins. bioRxiv. 2024 Dec 27;2024.12.27.630464."},{"issue":"4","key":"10626_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/0002-8703(81)90096-X","volume":"102","author":"MR Bristow","year":"1981","unstructured":"Bristow MR, Mason JW, Billingham ME et al (1981) Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102(4):709\u2013718","journal-title":"Am Heart J"},{"key":"10626_CR13","unstructured":"13. Bristow MR, Minobe WA, Billingham ME, et al. Anthracycline-associated cardiac and renal damage in rabbits. Lab Invest. 1981 Aug;45(2):157\u2013168."},{"issue":"2","key":"10626_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","volume":"88","author":"MR Bristow","year":"1978","unstructured":"Bristow MR, Mason JW, Billingham ME et al (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88(2):168\u2013175","journal-title":"Ann Intern Med"},{"key":"10626_CR15","doi-asserted-by":"crossref","unstructured":"15. Bristow MR, Mason JW, Billingham ME, et al. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer. 1982 Jul 1;50(5):32\u201341.","DOI":"10.1002\/1097-0142(19820701)50:1<32::AID-CNCR2820500108>3.0.CO;2-Q"},{"key":"10626_CR16","doi-asserted-by":"crossref","unstructured":"16. Bristow MR, Ginsburg RS, Mason JW, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205\u2013211.","DOI":"10.1056\/NEJM198207223070401"},{"issue":"6","key":"10626_CR17","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/01.CIR.74.6.1290","volume":"74","author":"MB Follin","year":"1986","unstructured":"Follin MB, Johnson JA, Hawkins GL et al (1986) Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74(6):1290\u20131302","journal-title":"Circulation"},{"key":"10626_CR18","doi-asserted-by":"crossref","unstructured":"18. Eisenberg EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circulation. 1996 Nov 1;94(9):2284\u20132296.","DOI":"10.1161\/01.CIR.94.9.2285"},{"key":"10626_CR19","doi-asserted-by":"crossref","unstructured":"19. Follin AM, Remond PE, Sade CM, et al. Selective gene expression in failing human heart. Circulation. 1991 Jun;83(6):1866\u20131872.","DOI":"10.1161\/01.CIR.83.6.1866"},{"issue":"10","key":"10626_CR20","first-page":"1852","volume":"84","author":"AM Follin","year":"1991","unstructured":"Follin AM (1991) Experimental issues in assessment of G protein function in cardiac disease. Circulation 84(10):1852\u20131861","journal-title":"Circulation"},{"key":"10626_CR21","doi-asserted-by":"crossref","unstructured":"21. Lever BD, Greer EM, Addon WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 2;346(18):1357\u20131365.","DOI":"10.1056\/NEJMoa012630"},{"issue":"11","key":"10626_CR22","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/BF03402039","volume":"8","author":"WT Arrieta","year":"2002","unstructured":"Arrieta WT, Greer EM, Lever BD et al (2002) Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 8(11):750\u2013760","journal-title":"Mol Med"},{"issue":"5","key":"10626_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.healun.2006.01.006","volume":"25","author":"BD Lever","year":"2006","unstructured":"Lever BD, Ziegler R, Mason WA et al (2006) Serial gene expression profiling in the intact human heart. J Heart Lung Transplant 25(5):579\u2013588","journal-title":"J Heart Lung Transplant"},{"key":"10626_CR24","doi-asserted-by":"crossref","unstructured":"24. Tomas LS, Cooper IA, Johnson KL, et al. Sequential analysis of myocardial gene expression with phenotypic change. PLoS One. 2019 Aug 30;14(8):e0221519.","DOI":"10.1371\/journal.pone.0221519"},{"key":"10626_CR25","doi-asserted-by":"crossref","unstructured":"25. Ammu NL, Baker AA, Smith CE, et al. Myocardial injury and altered gene expression associated with SARS-CoV-2 infection or mRNA vaccination. JACC Basic Transl Sci. 2023 Feb;8(2):124\u2013137.","DOI":"10.1016\/j.jacbts.2022.08.005"},{"key":"10626_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2026.101483","volume":"11","author":"DL Mann","year":"2026","unstructured":"Mann DL, Feldman AM, Fiuzat M, O\u2019Connor CM, Port JD (2026) Michael R. Bristow, MD, PhD: a translational pioneer who changed the field of heart failure. JACC Basic Transl Sci 11:101483","journal-title":"JACC Basic Transl Sci"},{"key":"10626_CR27","doi-asserted-by":"crossref","unstructured":"27. Myers JM, Prentice M, Fisher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002 Mar 14;346(11):793\u2013801.","DOI":"10.1056\/NEJMoa011858"},{"key":"10626_CR28","doi-asserted-by":"crossref","unstructured":"28. Hayes EJ, Smith S, Lekens JS, et al. Reversing the cardiac effects of sedentary aging in middle age. Circulation. 2018 Apr 10;137(15):1549\u20131560.","DOI":"10.1161\/CIRCULATIONAHA.117.030617"},{"key":"10626_CR29","doi-asserted-by":"crossref","unstructured":"29. Surette SC, Reue EP, Lanham MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012 May 8;125(18):2222\u20132231.","DOI":"10.1161\/CIRCULATIONAHA.111.067827"},{"key":"10626_CR30","doi-asserted-by":"crossref","unstructured":"30. Rosell LD, Barone P, Osborn JF, et al. \u03b2-Aminoisobutyric acid induces browning of white fat and hepatic \u03b2-oxidation. Cell Metab. 2014 Jan;19(1):209\u2013218.","DOI":"10.1016\/j.cmet.2013.12.003"},{"key":"10626_CR31","unstructured":"31. Swallow MA, Reid TK, Dion JP, et al. The HERITAGE Family Study: effects of exercise training on cardiometabolic health. Med Sci Sports Exerc. 2022 May;54(5S):S51-S143."},{"key":"10626_CR32","doi-asserted-by":"crossref","unstructured":"32. Chawla-Sarkar FJ, Nguyen N, Arora M, et al. Heart inflammation: immune cell roles and roads to the heart. Am J Pathol. 2019 Aug;189(8):1482\u20131494.","DOI":"10.1016\/j.ajpath.2019.04.009"},{"issue":"4","key":"10626_CR33","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","volume":"8","author":"T Naga","year":"2015","unstructured":"Naga T, Smith AM, Garcia-Perez A-P et al (2015) Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail 8(4):776\u2013787","journal-title":"Circ Heart Fail"},{"key":"10626_CR34","doi-asserted-by":"crossref","unstructured":"34. Li X, An P. Infarcted myocardium calls for T-cell help to regulate repair. Circ Res. 2023 Mar 3;132(5):583\u2013585.","DOI":"10.1161\/CIRCRESAHA.123.322556"},{"issue":"7752","key":"10626_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG, Altara F, Tong D et al (2019) Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568(7752):351\u2013356","journal-title":"Nature"},{"key":"10626_CR36","doi-asserted-by":"crossref","unstructured":"36. An P, Kumar M, Reddy E, et al. Myocardial inflammation in heart failure with reduced and preserved ejection fraction. Circ Res. 2024 Jun 7;134(12):1752\u20131766.","DOI":"10.1161\/CIRCRESAHA.124.323659"},{"key":"10626_CR37","doi-asserted-by":"crossref","unstructured":"37. Sharma S, Bansal AL, Kumar K, et al. Impaired T cell IRE1\u03b1\/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction. J Clin Invest. 2023 Dec 15;133(24):e171874.","DOI":"10.1172\/JCI171874"},{"key":"10626_CR38","doi-asserted-by":"crossref","unstructured":"38. Singh M, Gupta S, Rao R, et al. Hepato-cardiac interorgan communication controls cardiac hypertrophy via combined endocrine-autocrine FGF21 signaling. Cell Rep Med. 2025 Jun 17;6(6):102125.","DOI":"10.1016\/j.xcrm.2025.102125"},{"key":"10626_CR39","doi-asserted-by":"crossref","unstructured":"39. Sharma S, Ahmad NH, Lee SH, et al. FGF21 defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022 Mar;15(3):e008910.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008910"},{"key":"10626_CR40","doi-asserted-by":"crossref","unstructured":"40. Mendez-Ferrer E. Fatty liver and FGF21 physiology. Exp Cell Res. 2017 Nov 1;360(2):362\u2013365.","DOI":"10.1016\/j.yexcr.2017.05.006"},{"key":"10626_CR41","doi-asserted-by":"crossref","unstructured":"41. Patel A, Ivanov R, Hernandez E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019.","DOI":"10.1038\/ncomms3019"},{"key":"10626_CR42","doi-asserted-by":"crossref","unstructured":"42. Yamamoto J, Kobayashi O, Doi Y, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun. 2015 Mar 27;459(1):124\u2013130.","DOI":"10.1016\/j.bbrc.2015.02.081"},{"issue":"11","key":"10626_CR43","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1194\/jlr.M044784","volume":"55","author":"MK Bergmann","year":"2014","unstructured":"Bergmann MK, Anderson RC, Patel NM et al (2014) Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res 55(11):2229\u20132241","journal-title":"J Lipid Res"},{"key":"10626_CR44","doi-asserted-by":"crossref","unstructured":"44. Smith T, Zhao Y, Liu D, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016 Mar 8;23(3):427\u2013440.","DOI":"10.1016\/j.cmet.2016.02.001"},{"key":"10626_CR45","doi-asserted-by":"crossref","unstructured":"45. Garg G, Chen JY, Huang F, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013 Sep 3;18(3):333\u2013340.","DOI":"10.1016\/j.cmet.2013.08.005"},{"key":"10626_CR46","doi-asserted-by":"crossref","unstructured":"46. Smith A, Coleman ED, Nguyen-Tan BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019 Dec 22;392(10165):12705\u201312717.","DOI":"10.1016\/S0140-6736(18)31785-9"},{"key":"10626_CR47","doi-asserted-by":"crossref","unstructured":"47. Coleman ED, Nguyen-Tan BA, Johnson PF, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring). 2019 Jan;27(1):41\u201349.","DOI":"10.1002\/oby.22344"},{"issue":"7","key":"10626_CR48","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","volume":"29","author":"DL Brown","year":"2023","unstructured":"Brown DL, Edwards HE, Miller M et al (2023) The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med 29(7):1782\u20131792","journal-title":"Nat Med"},{"issue":"10","key":"10626_CR49","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jchf.2024.03.003","volume":"12","author":"OJ Ibrahim","year":"2024","unstructured":"Ibrahim OJ, Lopez P-B, Rao C et al (2024) Controversies and conundrums in cardiac cachexia: key questions about wasting in patients with HFrEF. JACC Heart Fail 12(10):1645\u20131660","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10626_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002881","volume":"9","author":"AR Verma","year":"2016","unstructured":"Verma AR, Kim PJ, Davis M et al (2016) Recovery of serum cholesterol predicts survival after left ventricular assist device implantation. Circ Heart Fail 9(9):e002881","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10626_CR51","volume":"15","author":"AR Verma","year":"2022","unstructured":"Verma AR, Wong WW, Chen J et al (2022) Skeletal muscle mass recovery early after left ventricular assist device implantation in patients with advanced systolic heart failure. Circ Heart Fail 15(5):e009012","journal-title":"Circ Heart Fail"},{"key":"10626_CR52","doi-asserted-by":"crossref","unstructured":"52. Lopez M, Patel J, Brown BA, et al. Growth differentiation factor-15 is associated with congestion-related anorexia and weight loss in advanced heart failure. JACC Heart Fail. 2025 Feb;13(2):315\u2013329.","DOI":"10.1016\/j.jchf.2024.10.023"},{"key":"10626_CR53","doi-asserted-by":"crossref","unstructured":"53. Kim NH, Park F, Chen RN, et al. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation. 2004 Jan 6;109(1):118\u2013122.","DOI":"10.1161\/01.CIR.0000111841.28126.D4"},{"issue":"1","key":"10626_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1183\/09031936.03.00054202","volume":"21","author":"F Park","year":"2003","unstructured":"Park F, An P, Varga JL et al (2003) Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J 21(1):31\u201336","journal-title":"Eur Respir J"},{"key":"10626_CR55","doi-asserted-by":"crossref","unstructured":"55. Kumar SA, Chen M, Varga JL, et al. Partitioning of pulmonary vascular resistance in primary pulmonary hypertension. J Am Coll Cardiol. 1998 May;31(5):1372\u20131376.","DOI":"10.1016\/S0735-1097(98)00091-6"},{"key":"10626_CR56","doi-asserted-by":"crossref","unstructured":"56. Foster AU, Edwards WD, Miller JJ, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation. 2018 Apr 24;137(17):1796\u20131810.","DOI":"10.1161\/CIRCULATIONAHA.117.031608"},{"key":"10626_CR57","doi-asserted-by":"crossref","unstructured":"57. Lewis GD, Davis N, Harrington AR, et al. Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension. J Am Coll Cardiol. 2016 Jan 19;67(2):174\u2013189.","DOI":"10.1016\/j.jacc.2015.10.072"},{"key":"10626_CR58","doi-asserted-by":"crossref","unstructured":"58. Brown B, Nguyen V, Anderson A, et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res. 2019 Aug 2;125(14):449\u2013466.","DOI":"10.1161\/CIRCRESAHA.118.314555"},{"issue":"6","key":"10626_CR59","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/HYPERTENSIONAHA.117.09123","volume":"69","author":"G Li","year":"2017","unstructured":"Li G, Zhang MC, Smith B et al (2017) Selective Nrf2 gene deletion in the rostral ventrolateral medulla evokes hypertension and sympathoexcitation in mice. Hypertension 69(6):1198\u20131206","journal-title":"Hypertension"},{"issue":"2","key":"10626_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/MCA.0000000000000187","volume":"26","author":"JA Lewis","year":"2015","unstructured":"Lewis JA (2015) Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. Coron Artery Dis 26(2):176\u2013183","journal-title":"Coron Artery Dis"},{"key":"10626_CR61","doi-asserted-by":"crossref","unstructured":"61. Chen JN, Lee TB, Ortiz MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819\u2013823.","DOI":"10.1056\/NEJM198409273111303"},{"issue":"5","key":"10626_CR62","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0735-1097(90)90252-K","volume":"15","author":"DW Foster","year":"1990","unstructured":"Foster DW, Brown WJ, Smith JS (1990) Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings. J Am Coll Cardiol 15(5):1125\u20131134","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10626_CR63","volume":"39","author":"D Nguyen","year":"2024","unstructured":"Nguyen D, Chen T, Li G et al (2024) Nrf2-Keap1 in cardiovascular disease: which is the cart and which the horse? Physiology Bethesda 39(5):30","journal-title":"Physiology Bethesda"},{"key":"10626_CR64","doi-asserted-by":"crossref","unstructured":"64. Chen T, Li G, Zhang MC, et al. Myocardial infarction-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure. Am J Physiol Heart Circ Physiol. 2018 May 1;314(5):H928-H939.","DOI":"10.1152\/ajpheart.00602.2017"},{"key":"10626_CR65","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627\u20131635","journal-title":"J Clin Invest"},{"key":"10626_CR66","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV et al (2023) Randomized, controlled trial of the FGF21 analogue Pegozafermin in NASH. N Engl J Med 389:998\u20131008","journal-title":"N Engl J Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10626-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10626-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10626-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:14:37Z","timestamp":1776150877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10626-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10626"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10626-2","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"S.G.D. serves as a consultant for Abbott Laboratories and Pfizer. S.G.D has received research support from Novartis and Merck. The remaining authors declare no competing interests or financial relationships.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"55"}}